- Gerry Muhle appointed CCO, effective immediately
Absci appointed former Galderma executive Gerry Muhle as Chief Commercial Officer. The company also reported Q3 2026 financial results and confirmed ABS-201 trial progress: 13-week interim data expected December 2026, full data early 2027. Phase 2 endometriosis trial planned for mid-2027. Cash runway into H2 2028.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.